Entera Bio Ltd.
Close on Oct 19, 2026
- Market cap
- $148.33M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | After market close | – | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | After market close | – | $-0.07 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | $0.07 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | After market close | – | $-0.06 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | After market close | $42.00K | $-0.06 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | After market close | $42.00K | $-0.08 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | After market close | – | – | – |
Press releases
Announcements Entera Bio filed with the SEC
Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Second Quarter 2026 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in
Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Corporate PresentationAugust 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Entera Bio Reports Third Quarter 2021 Financial Results
EX-99.1 to Form 6-K
Entera Bio Publishes Key Study Describing its Oral Delivery Technology
EX-99.1 to Form 6-K